September 23, 2024
QureTech Bio, a biotechnology company developing novel antibiotics, today announced a substantial investment from Kempestiftelserna. This investment enables QureTech Bio to continue its mission to develop innovative therapies that address the urgent global challenge of antimicrobial resistance.
With this financial support, QureTech Bio will be able to accelerate its research and development efforts of novel antibiotic treatments and bringing life-saving treatments closer to those who need them most. A total of SEK 14 million was invested in the company by Kempestiftelserna along with the company’s largest shareholder Nascent Invest.
The investment will specifically support QureTech Bio’s groundbreaking work in targeting infectious bacteria that have become resistant to conventional antibiotics. By leveraging cutting-edge technology and scientific expertise, the company is poised to make significant advancements in the field of antimicrobial resistance.
“We are happy to welcome such a reputable foundation as Kempestiftelserna as a shareholder,” says Markus Thor, CEO of QureTech Bio. “Their investment makes a true difference and is a testament to the importance of our work and the potential impact it can have on global health. This investment will enable us to accelerate our development programs.“
“We believe in the innovative approach of QureTech Bio and are proud to support the company’s efforts in fighting antimicrobial resistance,” comments Alice Kempe, Chairman of the board at Kempestiftelserna. “This partnership reflects our commitment to fostering advancements in medical research at and around Umeå University and thereby improving public health.”
Full PR available here.